{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:46:46Z","timestamp":1762314406345,"version":"build-2065373602"},"reference-count":99,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-21-150-01-CDP"],"award-info":[{"award-number":["RSG-21-150-01-CDP"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T15:44:15Z","timestamp":1751903055000},"page":"859-873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Chronic Lymphocytic Leukemia Epigenome"],"prefix":"10.1016","volume":"39","author":[{"given":"Antonio","family":"Perez-Castro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne V.","family":"Abruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2025.05.005_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"10.1016\/j.hoc.2025.05.005_bib2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.005_bib3","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.005_bib4","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"7574","key":"10.1016\/j.hoc.2025.05.005_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.005_bib6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2020007039","article-title":"Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL","volume":"137","author":"Agathangelidis","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.005_bib7","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.005_bib8","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors","volume":"102","author":"Fais","year":"1998","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.005_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000334","article-title":"Celebrating 20 Years of IGHV mutation analysis in CLL","volume":"4","author":"Chiorazzi","year":"2020","journal-title":"Hemasphere"},{"issue":"18","key":"10.1016\/j.hoc.2025.05.005_bib10","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.005_bib11","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","article-title":"Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia","volume":"100","author":"Chen","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.005_bib12","first-page":"1078","article-title":"ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia","volume":"90","author":"Corcoran","year":"2005","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.hoc.2025.05.005_bib13","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.2011.39.3090","article-title":"Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia","volume":"30","author":"Claus","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.005_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2014-02-555722","article-title":"Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia","volume":"124","author":"Claus","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.005_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4161\/epi.6.3.14038","article-title":"Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia","volume":"6","author":"Irving","year":"2011","journal-title":"Epigenetics"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.005_bib16","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ng.2443","article-title":"Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia","volume":"44","author":"Kulis","year":"2012","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.005_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ng.3488","article-title":"DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia","volume":"48","author":"Oakes","year":"2016","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.005_bib18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/leu.2014.252","article-title":"A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact","volume":"29","author":"Queiros","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.005_bib19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1182\/blood.2019000490","article-title":"Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia","volume":"134","author":"Giacopelli","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.005_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/11772719211067972","article-title":"Evaluation of a prognostic epigenetic classification system in chronic lymphocytic leukemia patients","volume":"17","author":"Grimm","year":"2022","journal-title":"Biomark Insights"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.005_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3324\/haematol.2021.278477","article-title":"IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load","volume":"107","author":"Hussmann","year":"2022","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.hoc.2025.05.005_bib22","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/bloodadvances.2019000237","article-title":"Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials","volume":"3","author":"Wojdacz","year":"2019","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.hoc.2025.05.005_bib23","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1158\/1078-0432.CCR-18-0133","article-title":"The light chain IgLV3-21 defines a new poor prognostic subgroup in chronic lymphocytic leukemia: results of a multicenter study","volume":"24","author":"Stamatopoulos","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.005_bib24","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1073\/pnas.1913810117","article-title":"IGLV3-21\u221701 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling","volume":"117","author":"Maity","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.005_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133045","article-title":"Immunoglobulin gene sequence as an inherited and acquired risk factor for chronic lymphocytic leukemia","volume":"14","author":"Datta","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.hoc.2025.05.005_bib26","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood.2020008311","article-title":"IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics","volume":"137","author":"Nadeu","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.005_bib27","doi-asserted-by":"crossref","first-page":"7384","DOI":"10.1182\/bloodadvances.2023010132","article-title":"IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia","volume":"7","author":"Syrykh","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.005_bib28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-022-00650-4","article-title":"Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21(R110) chronic lymphocytic leukemia","volume":"12","author":"Paschold","year":"2022","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.hoc.2025.05.005_bib29","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.2023022180","article-title":"Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature","volume":"143","author":"Abdelbaky","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.005_bib30","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"CLLIPIwg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.005_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood.2020009813","article-title":"The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL","volume":"138","author":"Parikh","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.005_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.005_bib33","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/10428194.2024.2449214","article-title":"Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the future","volume":"66","author":"McKeague","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1016\/j.hoc.2025.05.005_bib34","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.005_bib35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.005_bib36","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"36","key":"10.1016\/j.hoc.2025.05.005_bib37","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.005_bib38","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.005_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/hon.3106","article-title":"Richter transformation in chronic lymphocytic leukemia","volume":"41","author":"Innocenti","year":"2023","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.005_bib40","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/sj.leu.2404254","article-title":"Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL","volume":"20","author":"Strathdee","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.005_bib41","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/epi.11.73","article-title":"Epigenomics of leukemia: from mechanisms to therapeutic applications","volume":"3","author":"Florean","year":"2011","journal-title":"Epigenomics-Uk"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.005_bib42","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.cell.2007.03.043","article-title":"Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia","volume":"129","author":"Raval","year":"2007","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.005_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010338","article-title":"HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors","volume":"5","author":"Ghoshal","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.005_bib44","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4161\/epi.5.6.12179","article-title":"Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact","volume":"5","author":"Tong","year":"2010","journal-title":"Epigenetics"},{"key":"10.1016\/j.hoc.2025.05.005_bib45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2017.08.008","article-title":"Charting the dynamic epigenome during B-cell development","volume":"51","author":"Martin-Subero","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.005_bib46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","article-title":"Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage","volume":"30","author":"Queiros","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.005_bib47","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1101\/gr.180240.114","article-title":"Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers","volume":"25","author":"Agirre","year":"2015","journal-title":"Genome Res"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.005_bib48","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/ng.3291","article-title":"Whole-genome fingerprint of the DNA methylome during human B cell differentiation","volume":"47","author":"Kulis","year":"2015","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.005_bib49","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.3413","article-title":"DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control","volume":"47","author":"Kretzmer","year":"2015","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.005_bib50","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2018-02-692970","article-title":"Insight into origins, mechanisms, and utility of DNA methylation in B-cell malignancies","volume":"132","author":"Oakes","year":"2018","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.hoc.2025.05.005_bib51","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1038\/sj.onc.1205600","article-title":"CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future","volume":"21","author":"Esteller","year":"2002","journal-title":"Oncogene"},{"issue":"35","key":"10.1016\/j.hoc.2025.05.005_bib52","doi-asserted-by":"crossref","first-page":"12979","DOI":"10.1073\/pnas.0806437105","article-title":"Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line","volume":"105","author":"Gal-Yam","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.005_bib53","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41591-018-0028-4","article-title":"The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia","volume":"24","author":"Beekman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2025.05.005_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.14","article-title":"Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development","volume":"5","author":"Smith","year":"2015","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.005_bib55","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3324\/haematol.2013.098384","article-title":"The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy","volume":"99","author":"Packham","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.005_bib56","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/10428194.2017.1370548","article-title":"Regulation of MAPK signaling and implications in chronic lymphocytic leukemia","volume":"59","author":"Shukla","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"10.1016\/j.hoc.2025.05.005_bib57","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1111\/bph.13949","article-title":"Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas","volume":"174","author":"Janovska","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.005_bib58","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI93801","article-title":"Drug-perturbation-based stratification of blood cancer","volume":"128","author":"Dietrich","year":"2018","journal-title":"J Clin Investig"},{"key":"10.1016\/j.hoc.2025.05.005_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11938","article-title":"Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks","volume":"7","author":"Rendeiro","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.005_bib60","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41467-020-20849-y","article-title":"Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation","volume":"12","author":"Vilarrasa-Blasi","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.005_bib61","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.ccell.2018.11.001","article-title":"Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia","volume":"34","author":"Ott","year":"2018","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.005_bib62","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20188339","article-title":"Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks","volume":"15","author":"Mallm","year":"2019","journal-title":"Mol Syst Biol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.005_bib63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcmd.2014.07.013","article-title":"Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia","volume":"54","author":"Rabello Ddo","year":"2015","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.005_bib64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.yexmp.2018.07.009","article-title":"EZH2 is upregulated in the proliferation centers of CLL\/SLL lymph nodes","volume":"105","author":"Szurian","year":"2018","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.hoc.2025.05.005_bib65","article-title":"Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2025.05.005_bib66","doi-asserted-by":"crossref","first-page":"35946","DOI":"10.18632\/oncotarget.9371","article-title":"The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia","volume":"7","author":"Papakonstantinou","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.005_bib67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41389-019-0142-2","article-title":"Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells","volume":"8","author":"Holmes","year":"2019","journal-title":"Oncogenesis"},{"issue":"22","key":"10.1016\/j.hoc.2025.05.005_bib68","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1038\/sj.emboj.7600414","article-title":"Histone hypomethylation is an indicator of epigenetic plasticity in quiescent lymphocytes","volume":"23","author":"Baxter","year":"2004","journal-title":"EMBO J"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.005_bib69","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41408-022-00690-w","article-title":"B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.005_bib70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.005_bib71","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1101\/gr.269233.120","article-title":"DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia","volume":"31","author":"Giacopelli","year":"2021","journal-title":"Genome Res"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.005_bib72","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2013-14-9-r105","article-title":"Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia","volume":"14","author":"Nordlund","year":"2013","journal-title":"Genome Biol"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.005_bib73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13073-014-0066-6","article-title":"Pan-cancer patterns of DNA methylation","volume":"6","author":"Witte","year":"2014","journal-title":"Genome Med"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.005_bib74","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1365-2141.1996.d01-1478.x","article-title":"Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients","volume":"92","author":"Matutes","year":"1996","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.005_bib75","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.3324\/haematol.2018.190132","article-title":"Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways","volume":"103","author":"Abruzzo","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.005_bib76","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.3324\/haematol.2019.240721","article-title":"Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation","volume":"105","author":"Tsagiopoulou","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.005_bib77","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.005_bib78","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/leu.2017.177","article-title":"Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups","volume":"32","author":"Burns","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.005_bib79","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2403294","article-title":"High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia","volume":"18","author":"Heintel","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.005_bib99","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1182\/blood-2002-09-2906","article-title":"High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia","volume":"101","author":"McCarthy","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.005_bib80","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.leu.2404183","article-title":"Richter\u2019s and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation","volume":"20","author":"Reiniger","year":"2006","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.005_bib81","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41375-019-0446-4","article-title":"Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia","volume":"33","author":"Jebaraj","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.005_bib82","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41375-019-0389-9","article-title":"Telomere length predicts for outcome to FCR chemotherapy in CLL","volume":"33","author":"Norris","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.005_bib83","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2159-8290.CD-13-0349","article-title":"Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia","volume":"4","author":"Oakes","year":"2014","journal-title":"Cancer Discov"},{"issue":"7574","key":"10.1016\/j.hoc.2025.05.005_bib84","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.005_bib85","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41588-022-01211-y","article-title":"Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features","volume":"54","author":"Robbe","year":"2022","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.005_bib86","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s40142-019-00178-3","article-title":"Advances in epigenetics and epigenomics in chronic lymphocytic leukemia","volume":"7","author":"Xanthopoulos","year":"2019","journal-title":"Curr Genet Med Rep"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.005_bib87","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/leu.2016.356","article-title":"IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus","volume":"31","author":"Drennan","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.005_bib88","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3324\/haematol.2022.281869","article-title":"Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia","volume":"108","author":"Lutge","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.005_bib89","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s43018-020-00131-2","article-title":"The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome","volume":"1","author":"Duran-Ferrer","year":"2020","journal-title":"Nat Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.005_bib90","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s43018-021-00216-6","article-title":"Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia","volume":"2","author":"Lu","year":"2021","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.005_bib91","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/leu.2016.10","article-title":"Longitudinal copy number, whole exome and targeted deep sequencing of \u2018good risk\u2019 IGHV-mutated CLL patients with progressive disease","volume":"30","author":"Rose-Zerilli","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.005_bib92","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2643-3230.BCD-19-0058","article-title":"Preneoplastic alterations define CLL DNA methylome and persist through disease progression and therapy","volume":"2","author":"Kretzmer","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.005_bib93","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/leu.2012.245","article-title":"450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments","volume":"27","author":"Cahill","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.005_bib94","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.005_bib95","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/bloodadvances.2019000817","article-title":"CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation","volume":"4","author":"Bartholdy","year":"2020","journal-title":"Blood Adv"},{"issue":"7757","key":"10.1016\/j.hoc.2025.05.005_bib96","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-019-1198-z","article-title":"Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia","volume":"569","author":"Gaiti","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.005_bib97","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.005_bib98","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:42:43Z","timestamp":1762314163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000772"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Chronic Lymphocytic Leukemia Epigenome","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}